Black Diamond Therapeutics, Inc. (BDTX) Q1 2026 Earnings
BDTX·Reported May 7, 2026·After market close
Diluted EPS came in at $-0.16, beat the $-0.18 consensus by $0.02.
Diluted EPS
$-0.16beat by $0.02
Consensus: $-0.18
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Black Diamond Therapeutics, Inc.'s Q1 2026 earnings report.
Black Diamond Therapeutics, Inc. (BDTX) reported Q1 2026 earnings on May 7, 2026 after market close.
Black Diamond Therapeutics, Inc. reported diluted EPS of $-0.16 for Q1 2026.
EPS beat the consensus estimate of $-0.18 by $0.02.
You can read the 8-K earnings release (0001701541-26-000015) and the 10-Q periodic report (0001701541-26-000017) directly on SEC EDGAR. The filing index links above go to sec.gov.